Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 136

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 136
---
 first six months of 2024, compared to £4,000 in the first six months of 2023. Capital expenditures in
2023 related to laboratory equipment. In addition, we acquired the eRapa license for total consideration of £3.07 million including
cash consideration of £0.85 million. These cash outflows are offset by interest income from bank deposits of £0.10 million.

Purchase of property, plant and equipment of £0.03 million occurred in the year ended December 31, 2023, compared to £0.06 million in 2022. In addition, we acquired the tolimidone license for total consideration of £2.94 million, including cash of £0.24 million. These cash outflows are offset interest income from bank deposits of £0.07 million.

Financing Activities

Amounts paid on lease liabilities.In the six months ended June 30 2024 we paid £93,000 in respect of lease liabilities compared
with £95,000 in the prior period.

In 2023 we paid £0.19 million in respect
of lease liabilities compared with £0.18 million in 2022, this related to rental payments on our facilities in Cardiff.

Shares Issues Including Warrants, Net of Costs. We raised £4.74 million in net proceeds in the six months ended June 30, 2024
from a warrant inducement transaction in May 2024 private placement. We raised £6.35 million in net proceeds in the six months ended
June 30, 2023 from a private placement in February 2023 and a registered direct offering in May 2023, as well as from warrants exercises.

We
raised £10.43 million in net proceeds during the year ended December 31, 2023 in cash from private placements of our securities,
a registered direct offering and an underwritten public offering, as well as from the exercise of warrants. We raised £0.24 million
in net proceeds during the year ended December 31, 2022 in cash from the registered direct offering in December 2022 and from the exercise
of warrants.

Cash and Cash Equivalents

Cash decreased for the six
months ended June 30, 2024 by £0.92 million, compared to an increase of £2.39 million in the corresponding period in 2023.
As at June 30, 2024, we had cash and cash equivalents of £5